Literature DB >> 9823341

Marijuana smoking vs cannabinoids for glaucoma therapy.

K Green1.   

Abstract

OBJECTIVE: To discuss the clinical effects, including toxicological data, of marijuana and its many constituent compounds on the eye and the remainder of the body. A perspective is given on the use of marijuana and the cannabinoids in the treatment of glaucoma.
RESULTS: Although it is undisputed that smoking of marijuana plant material causes a fall in intraocular pressure (IOP) in 60% to 65% of users, continued use at a rate needed to control glaucomatous IOP would lead to substantial systemic toxic effects revealed as pathological changes.
CONCLUSIONS: Development of drugs based on the cannabinoid molecule or its agonists for use as topical or oral antiglaucoma medications seems to be worthy of further pursuit. Among the latter chemicals, some have no known adverse psychoactive side effects. Smoking of marijuana plant material for the reduction of elevated IOP in glaucoma is ill-advised, given its toxicological profile.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9823341     DOI: 10.1001/archopht.116.11.1433

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  17 in total

Review 1.  The use of marijuana to treat glaucoma.

Authors:  Charles M Lederer
Journal:  Mo Med       Date:  2012 Mar-Apr

2.  The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice.

Authors:  Elizabeth A Cairns; Anna-Maria Szczesniak; Alex J Straiker; Pushkar M Kulkarni; Roger G Pertwee; Ganesh A Thakur; William H Baldridge; Melanie E M Kelly
Journal:  J Ocul Pharmacol Ther       Date:  2017-07-18       Impact factor: 2.671

3.  Cannabis, a complex plant: different compounds and different effects on individuals.

Authors:  Zerrin Atakan
Journal:  Ther Adv Psychopharmacol       Date:  2012-12

Review 4.  Cannabinoids in clinical practice.

Authors:  E M Williamson; F J Evans
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

5.  Synthesis and evaluation of potent and selective MGL inhibitors as a glaucoma treatment.

Authors:  Shakiru O Alapafuja; Michael S Malamas; Vidyanand Shukla; Alexander Zvonok; Sally Miller; Laura Daily; Girija Rajarshi; Christina Yume Miyabe; Honrao Chandrashekhar; JodiAnne Wood; Sergiy Tyukhtenko; Alex Straiker; Alexandros Makriyannis
Journal:  Bioorg Med Chem       Date:  2018-11-03       Impact factor: 3.641

Review 6.  Medical marijuana initiatives : are they justified? How successful are they likely to be?

Authors:  Wayne Hall; Louisa Degenhardt
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

7.  Involvement of a non-CB1/CB2 cannabinoid receptor in the aqueous humor outflow-enhancing effects of abnormal-cannabidiol.

Authors:  Zhuanhong Qiao; Akhilesh Kumar; Pritesh Kumar; Zhao-Hui Song
Journal:  Exp Eye Res       Date:  2012-05-08       Impact factor: 3.467

8.  Effects of palmitoylethanolamide on aqueous humor outflow.

Authors:  Akhilesh Kumar; Zhuanhong Qiao; Pritesh Kumar; Zhao-Hui Song
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-03       Impact factor: 4.799

9.  Alternative therapy in glaucoma management: is there any role?

Authors:  Rajul S Parikh; Shefali R Parikh
Journal:  Indian J Ophthalmol       Date:  2011-01       Impact factor: 1.848

10.  Δ9-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits.

Authors:  Pranjal S Taskar; Akash Patil; Prit Lakhani; Eman Ashour; Waseem Gul; Mahmoud A ElSohly; Brian Murphy; Soumyajit Majumdar
Journal:  Transl Vis Sci Technol       Date:  2019-09-19       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.